Alpha Tau Reports Responses in 6 Patients in Interim Brain Cancer Trial Results
Key Facts
Alpha Tau Medical announced on November 15 interim results from the U.S. REGAIN trial for glioblastoma, based on data cut off on November 11. The company said all six patients who reached the response-assessment stage achieved an objective response under RANO criteria, an early clinical signal from an ongoing trial. The results included five complete responses and one partial response, in which the patient's tumor measurements declined by 58%. The reading is based on a small group of patients, and some responses still require imaging follow-up. At its current stage, the trial is focused primarily on feasibility and safety, alongside the collection of additional response and survival data.
The company said the first three complete responses were confirmed in subsequent scans, while the three most recent responses were observed in early assessments and still need confirmation in later imaging. This means the reported response total combines confirmed results with preliminary ones, according to the update published on November 15. The six patients whose responses could be assessed had a median follow-up of 6.9 months as of the data cutoff, ranging from 3.1 to 11.6 months. All eight patients who received treatment were alive as of November 11, and median overall survival had not been reached. Continued follow-up of these patients is needed to assess the durability of responses and the development of survival measures.
On imaging, the company observed necrosis or suspected necrosis in or around the treatment area in four of the six patients, and said these cases were not accompanied by symptoms. Researchers have not yet been able to determine whether the visible changes in two patients represent necrosis or tumor progression. The question remains open pending follow-up scan results, making image interpretation part of the assessment of the responses themselves. On implementation, the planned Alpha DaRT sources were successfully placed in all eight patients. The company said it had not observed any unexpected serious adverse events, but reported a previously disclosed Grade 3 serious adverse event in May: a seizure with Todd's paralysis that resolved after treatment.
The REGAIN trial is open and ongoing. In October, the target enrollment was expanded from 10 to 20 patients, with approval from the U.S. Food and Drug Administration, across three U.S. academic centers. The protocol adds periodic quality-of-life assessments and measurement of progression-free survival. Alpha Tau said enrollment and follow-up are continuing and that it expects additional follow-up scans to become available in the coming months. In its second-quarter financial update, the company had targeted completing REGAIN enrollment in the second half of 2026, with additional data near year-end. It also listed expected preliminary data from the IMPACT and ReSTART studies in late 2026 or early 2027 among its stated targets.
The results remain interim in the context of a clinical development program. In its financial filing, the company cautioned that preliminary trial results may not predict final outcomes and said it expects to incur significant losses in the coming years during development. Alpha DaRT has not received marketing approval for glioblastoma in the United States, and its use remains limited to approved clinical trials. In the background to the trial, a preliminary analysis published in May of three patients showed local disease control in all three cases, with two complete responses and one stable case in which tumor measurements declined by 30%. The company's shares, listed under the ticker DRTS, closed at $12.09 on November 17, according to EL7 data. The company's upcoming listed events include the Piper Sandler Healthcare Conference from December 1 to 3, 2026, followed by the JPMorgan Healthcare Conference from January 11 to 14, 2027.